CSF markers for incipient Alzheimer's disease

Lancet Neurology

Volumn 2, Issue 10, 2003, Pages 605-613

  Blennow, Kaj ^a,c   Hampel, Harald ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; TAU PROTEIN;

ALZHEIMER DISEASE; ANALYTIC METHOD; BIOSAFETY; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFECT; HEADACHE; HUMAN; LUMBAR PUNCTURE; MEDICAL PRACTICE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 0141738373     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00530-1     Document Type: Review

References (89)

1. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 56:1999;303-308.
2. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2:2003;15-21.
3. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 34:1984;939-944.
4. Galasko D., Hansen L.A., Katzman R., et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol. 51:1994;888-895.
5. Jellinger K.A. Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol. 91:1996;219-220.
6. Davies L., Wolska B., Hilbich C., et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 38:1988;1688-1693.
7. Hesse C., Rosengren L., Vanmechelen E., et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimer Dis. 2:2000;199-206.
8. Otto M., Wiltfang J., Tumani H., et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 225:1997;210-212.
9. Blennow K., Wallin A., Ågren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol. 26:1995;231-245.
10. Wolf H., Jelic V., Gertz H.J., Nordberg A., Julin P., Wahlund L.O. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand. 107:(suppl 179):2003;52-76.
11. Gottfries J., Blennow K., Lehmann M.W., et al. One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis. J Geriatr Psychiatry Neurol. 14:2001;109-114.
12. Maruyama M., Arai H., Sugita M., et al. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol. 172:2001;433-436.
13. Buerger K., Teipel S.J., Zinkowski R., et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 59:2002;627-629.
14. Okamura N., Arai H., Maruyama M., et al. Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry. 159:2002;474-476.
15. Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand. 107:(suppl 179):2003;47-51.
16. Vandermeeren M., Mercken M., Vanmechelen E., et al. Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 61:1993;1828-1834.
17. Vigo-Pelfrey C., Seubert P., Barbour R., et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 45:1995;788-793.
18. Masters C.L., Simms G., Weinman N.A., et al. Amyloid plaque core protein in Alzheimer's disease and Down syndrome. Proc Natl Acad Sci USA. 82:1985;4245-4249.
19. van Nostrand W.E., Wagner S.L., Shankle W.R., et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci USA. 89:1992;2551-2555.
20. Farlow M., Ghetti B., Benson M.D., et al. Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer's disease. Lancet. 340:1992;453-454.
21. van Gool W.A., Kuiper M.A., Walstra G.J., Wolters E.C., Bolhuis P.A. Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 37:1995;277-279.
22. Miller D.L., Papayannopoulos I.A., Styles J., Bobin S.A., Lin Y.Y., Biemann K., Iqbal K. Peptide composition of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys. 301:1993;41-52.
23. Roher A.E., Palmer K.C., Yurewicz E.C., Ball M.J., Greenberg B.D. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem. 61:1993;1916-1926.
24. (1-42). Fisher A., Hanin I., Yoshida M. CSF: progress in Alzheimer's and Parkinson's diseases. 1998;773-778 New York, Plenum Press.
25. Motter R., Vigo-Pelfrey C., Kholodenko D., et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 38:1995;643-648.
26. Otto M., Esselmann H., Schulz-Shaeffer W., et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology. 54:2000;1099-1102.
27. Sjögren M., Davidsson P., Wallin A., et al. Decreased CSF β-amyloid42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by separate mechanisms. Dementia Geriatr Cogn Disord. 13:2002;112-118.
28. Holmberg B., Johnels B., Blennow K., Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord. 18:2003;186-190.
29. Strozyk D., Blennow K., White L.R., Launer L.J. CSF Aβ42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 60:2003;652-656.
30. Vanmechelen E., Vanderstichele H., Davidsson P., et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 285:2000;49-52.
31. Ishiguro K., Ohno H., Arai H., et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett. 270:1999;91-94.
32. Kohnken R., Buerger K., Zinkowski R., et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 287:2000;187-190.
33. Hu Y.Y., He S.S., Wang X., et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol. 160:2002;1269-1278.
34. Hesse C., Rosengren L., Andreasen N., et al. Transient increase in CSF total tau but not phospho-tau after acute stroke. Neurosci Lett. 297:2001;187-190.
35. Riemenschneider M., Wagenpfeil S., Vanderstichele H., et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry. 8:2003;343-347.
36. Shoji M., Matsubara E., Kanai M., et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci. 158:1998;134-140.
37. Kanai M., Matsubara E., Isoe K., et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol. 44:1998;17-26.
38. Tapiola T., Lehtovirta M., Ramberg J., et al. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. Neurology. 50:1998;169-174.
39. Shoji M., Matsubara E., Murakami T., et al. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol Aging. 23:2002;363-370.
40. Kahle P.J., Jakowec M., Teipel S.J., et al. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology. 54:2000;1498-1504.
41. Schönknecht P., Pantel J., Hunt A., et al. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci Lett. 339:2003;172-174.
42. Nishimura T., Takeda M., Nakamura Y., et al. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find Exp Clin Pharmacol. 20:1998;227-235.
43. Sjögren M., Rosengren L., Minthon L., Davidsson P., Blennow K., Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from Alzheimer's disease. Neurology. 54:2000;1960-1964.
44. Green A.J., Harvey R.J., Thompson E.J., Rossor M.N. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett. 259:1999;133-135.
45. Sjögren M., Davidsson P., Gottfries J., et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord. 12:2001;257-264.
46. Hulstaert F., Blennow K., Ivanoiu A., et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology. 52:1999;1555-1562.
47. Sjögren M., Minthon L., Davidsson P., et al. CSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm. 107:2000;563-579.
48. Hampel H., Teipel S.J., Padberg F., et al. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease. Brain Res. 823:1999;104-112.
49. Buerger K., Zinkowski R., Teipel S.J., et al. Differential diagnosis of Alzheimer's disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 59:2002;1267-1272.
50. Kanemaru K., Kameda N., Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology. 54:2000;1875-1876.
51. Buerger nee Buch K., Padberg F., Nolde T., et al. Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. Neurosci Lett. 277:1999;21-24.
52. Sjögren M., Davidsson P., Tullberg M., et al. Both total and hyperphosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 70:2001;624-630.
53. Rosler N., Wichart I., Jellinger K.A. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 60:1996;237-238.
54. Kapaki E., Paraskevas G.P., Zalonis I., Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur J Neurol. 10:2003;119-128.
55. Arai H., Satoh-Nakagawa T., Higuchi M., et al. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci Lett. 256:1998;174-176.
56. Kurz A., Riemenschneider M., Buch K., et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest stage of Alzheimer disease. Alzheimer Dis Assoc Disord. 12:1998;372-377.
57. Rosler N., Wichart I., Jellinger K.A. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. J Neural Transm. 108:2001;231-246.
58. Kapaki E., Kilidireas K., Paraskevas G.P., Michalopoulou M., Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry. 71:2001;401-403.
59. Mulder C., Schoonenboom S.N., Wahlund L.O., et al. CSF markers related to pathogenetic mechanisms in Alzheimer's disease. J Neural Transm. 109:2002;1491-1498.
60. Morikawa Y., Arai H., Matsushita S., et al. Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. Alcohol Clin Exp Res. 23:1999;575-577.
61. Andreasen N., Minthon L., Clarberg A., et al. Sensitivity, specificity and stability of CSF t-tau in AD in a community-based patient sample. Neurology. 53:1999;1488-1494.
62. Andreasen N., Vanmechelen E., Van de Voorde A., et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community-based follow-up study. J Neurol Neurosurg Psychiatry. 64:1998;298-305.
63. Riemenschneider M., Wagenpfeil S., Diehl J., et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology. 58:2002;1622-1628.
64. Riemenschneider M., Buch K., Schmolke M., Kurz A., Guder W.G. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett. 212:1996;209-211.
65. Arai H., Terajima M., Miura M., et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol. 38:1995;649-652.
66. Martinez M., Fernandez E., Frank A., Guaza C., de la Fuente M., Hernanz A. Increased cerebrospinal fluid cAMP levels in Alzheimer's disease. Brain Res. 846:1999;265-267.
67. Munroe W.A., Southwick P.C., Chang L., et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci. 25:1995;207-217.
68. Galasko D., Chang L., Motter R., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 55:1998;937-945.
69. Galasko D., Clark C., Chang L., et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 48:1997;632-635.
70. Jellinger K.A. Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol. 91:1996;219-220.
71. Kosunen O., Soininen H., Paljärvi L., et al. Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol. 91:1996;185-193.
72. (1-42) in Alzheimer's disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 56:1999;673-680.
73. Andreasen N., Minthon L., Vanmechelen E., et al. CSF t-tau and CSF-Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett. 273:1999;5-8.
74. Parnetti L., Lanari A., Amici S., Gallai V., Vanmechelen E., Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies.@, Phospho-Tau International Study Group. Neurol Sci. 22:2001;77-78.
75. Itoh N., Arai H., Urakami K., et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol. 50:2001;150-156.
76. Buerger K., Zinkowski R., Teipel S.J., et al. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am J Psychiatry. 160:2003;376-379.
77. Folstein M., Folstein S., McHugh P.@,. "Mini Mental State" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12:1975;189-198.
78. Arai H., Ishiguro K., Ohno H., et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol. 166:2000;201-203.
79. Arai H., Nakagawa T., Kosaka Y., et al. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients. Alzheimer's Res. 3:1997;211-213.
80. Lautenschlager N.T., Riemenschneider M., Drzezga A. Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings. Dement Geriatr Cogn Disord. 12:2001;379-386.
81. Andreasen N., Minthon L., Davidsson P., et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch Neurol. 58:2001;373-379.
82. Riemenschneider M., Lautenschlager N., Wagenpfeil S., Diehl J., Drzezga A., Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 59:2002;1729-1734.
83. Lopez O.L., Becker J.T., Kaufer D.I., et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol. 59:2002;43-46.
84. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 45:1999;358-368.
85. 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 289:2003;2094-2103.
86. Vandam L.D., Dripps R.D. Long-term follow-up of patients who received 10,098 spinal anesthetics. JAMA. 161:1956;586-591.
87. Blennow K., Wallin A., Häger O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand. 88:1993;221-223.
88. Hampel H., Buerger K., Kohnken R., et al. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol. 49:2001;545-546.
89. de Leon M.J., Segal S., Tarshish C.Y., et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett. 333:2002;183-186.